Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Feb 15;66(2):e0166421.
doi: 10.1128/AAC.01664-21. Epub 2021 Nov 22.

Randomized Controlled Study of Tenofovir versus Lamivudine Followed by Tenofovir in Severe Exacerbation of Hepatitis B

Chia-Ming Lu  1   2 , Jin-Shiung Cheng  1   2 , Wei-Chih Sun  1   2 , Wen-Chi Chen  1   2 , Feng-Woei Tsay  1   2 , Huay-Min Wang  1   2 , Tzung-Jiun Tsai  1   2 , Sung-Shuo Kao  1   2 , Yun-Da Li  1   2 , Yuan-Rong Li  1   2 , Huey-Shyan Lin  3 , Chun-Hao Yin  4 , Wei-Lun Tsai  1   2
Affiliations
Randomized Controlled Trial

Randomized Controlled Study of Tenofovir versus Lamivudine Followed by Tenofovir in Severe Exacerbation of Hepatitis B

Chia-Ming Lu et al. Antimicrob Agents Chemother. .

Abstract

Spontaneous severe acute exacerbation (SAE) is not uncommon in the natural history of chronic hepatitis B (CHB). Lamivudine (LAM) has the advantages of low price, quick onset, good efficacy, and no drug resistance within 24 weeks. This study aimed to compare the short-term efficacy of tenofovir disoproxil fumarate (TDF) and LAM for 24 weeks followed by TDF in the treatment of CHB with severe acute exacerbation. Consecutive patients of CHB with SAE were randomized to receive either TDF (19 patients) or LAM for 24 weeks, followed by TDF (18 patients). The primary endpoint was overall mortality or receipt of liver transplantation by week 24. This study was approved by the Institutional Review Board (IRB) of the Kaohsiung Veterans General Hospital (VGHKS12-CT5-10). The baseline characteristics were comparable between the two groups. By week 24, seven (37%) and five (28%) patients in the TDF and LAM-TDF groups died or received liver transplantation (P = 0.487). Multivariate analysis showed that albumin level, prothrombin time (PT), and hepatic encephalopathy were independent factors associated with mortality or liver transplantation by week 24. Early reductions in HBV DNA of more than or equal to 2 log at 1 and 2 weeks were similar between the two groups. The biochemical and virological responses at 12, 24, and 48 weeks were also similar between the two groups. TDF and LAM for 24 weeks followed by TDF achieved a similar clinical outcome in CHB patients with SAE. (This study has been registered at ClinicalTrials.gov under identifier NCT01848743).

Keywords: acute exacerbation; exacerbation; hepatitis B virus; lamivudine; tenofovir disoproxil fumarate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIG 1
FIG 1
Flow of study participants who received TDF or LAM followed by TDF.
FIG 2
FIG 2
Cumulative rates of overall mortality or liver transplantation by week 24 in patients treated with tenofovir disoproxil fumarate and lamivudine.
FIG 3
FIG 3
Two-log reduction in HBV DNA levels at 1 and 2 weeks and mortality or liver transplantation in TDF or lamivudine/TDF group.
FIG 4
FIG 4
Virological responses at 12, 24, and 48 weeks in CHB patients with SAE who received TDF or lamivudine for 24 weeks followed by TDF.
FIG 5
FIG 5
Biochemical responses at 12, 24, and 48 weeks in CHB patients with SAE who received TDF or lamivudine for 24 weeks followed by TDF.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Lee WM. 1997. Hepatitis B virus infection. N Engl J Med 337:1733–1745. 10.1056/NEJM199712113372406. - DOI - PubMed
    1. Seto WK, Lo YR, Pawlotsky JM, Yuen MF. 2018. Chronic hepatitis B virus infection. Lancet 392:2313–2324. 10.1016/S0140-6736(18)31865-8. - DOI - PubMed
    1. Tang LSY, Covert E, Wilson E, Kottilil S. 2018. Chronic hepatitis B infection: a review. JAMA 319:1802–1813. 10.1001/jama.2018.3795. - DOI - PubMed
    1. Lok AS, Lai CL. 1990. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 10:29–34. 10.1016/0168-8278(90)90069-4. - DOI - PubMed
    1. Liaw YF. 1995. Acute exacerbation and superinfection in patients with chronic viral hepatitis. J Formos Med Assoc 94:521–528. - PubMed

Publication types

Associated data